Amy Simon
About
Amy Simon is a scholar working on Molecular Biology, Surgery and Oncology.
According to data from OpenAlex, Amy Simon has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 10 papers in Surgery and 9 papers in Oncology. Recurrent topics in Amy Simon's work include Porphyrin Metabolism and Disorders (12 papers), Heme Oxygenase-1 and Carbon Monoxide (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Amy Simon is often cited by papers focused on Porphyrin Metabolism and Disorders (12 papers), Heme Oxygenase-1 and Carbon Monoxide (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Amy Simon collaborates with scholars based in United States, United Kingdom and Australia. Amy Simon's co-authors include Brent Cochran, Barry L. Fanburg, Usha Rai, Mariano Severgnini, Valerie A. Clausen, Akshay Vaishnaw, Kevin Fitzgerald, Brian R. Bettencourt, Jay D. Horton and Satoe Takahashi and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.
In The Last Decade
Amy Simon
40 papers receiving 3.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amy Simon United States | 19 | 1.5k | 744 | 588 | 483 | 466 | 42 | 3.1k | ||
| Masatoshi Kusuhara Japan | 32 | 1.6k 1.1× | 515 0.7× | 631 1.1× | 584 1.2× | 636 1.4× | 123 | 3.5k | ||
| Wolfgang Erl Germany | 27 | 1.7k 1.1× | 803 1.1× | 961 1.6× | 422 0.9× | 801 1.7× | 40 | 3.7k | ||
| Alistair J. Ingram Canada | 38 | 2.1k 1.4× | 350 0.5× | 362 0.6× | 395 0.8× | 532 1.1× | 73 | 3.8k | ||
| Jiawei Chen China | 32 | 1.3k 0.9× | 390 0.5× | 1.0k 1.7× | 365 0.8× | 727 1.6× | 131 | 3.2k | ||
| Peter Ellinghaus Germany | 28 | 1.6k 1.1× | 519 0.7× | 217 0.4× | 444 0.9× | 544 1.2× | 74 | 3.1k | ||
| Orina Belton Ireland | 25 | 982 0.7× | 434 0.6× | 597 1.0× | 196 0.4× | 380 0.8× | 41 | 2.8k | ||
| Yabing Chen United States | 26 | 1.2k 0.8× | 301 0.4× | 354 0.6× | 337 0.7× | 401 0.9× | 54 | 2.6k | ||
| Shiro Kitamoto Japan | 31 | 1.3k 0.9× | 762 1.0× | 1.2k 2.1× | 622 1.3× | 608 1.3× | 52 | 3.8k | ||
| Aijun Sun China | 35 | 1.7k 1.2× | 791 1.1× | 550 0.9× | 219 0.5× | 465 1.0× | 130 | 3.8k | ||
| Naomi Sakashita Japan | 29 | 955 0.6× | 698 0.9× | 379 0.6× | 262 0.5× | 255 0.5× | 71 | 2.3k |
Countries citing papers authored by Amy Simon
Since
Specialization
Citations
This map shows the geographic impact of Amy Simon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Simon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Simon more than expected).
Fields of papers citing papers by Amy Simon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Amy Simon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Simon. The network helps show where Amy Simon may publish in the future.
Co-authorship network of co-authors of Amy Simon
This figure shows the co-authorship network connecting the top 25 collaborators of Amy Simon. A scholar is included among the top collaborators of Amy Simon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Simon. Amy Simon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chockalingam, Priya, Ling Lin, Chen Guo, et al.. (2024). Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial Data from the BEACON Phase 1/2 Study of Autologous CD34+ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease. Blood. 144(Supplement 1). 4957–4957.
2.
Diorio, Caroline, Paul Shaughnessy, Nosha Farhadfar, et al.. (2024). BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T-Cells. Blood. 144(Supplement 1). 4838–4838.
3.
Gill, Liz, et al.. (2022). Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts. Advances in Therapy. 39(9). 4330–4345.
4.
Anderson, Karl E., et al.. (2020). 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin. Molecular Genetics and Metabolism. 131(4). 418–423.
5.
Simon, Amy, Farrah Pompilus, William Querbes, et al.. (2018). Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. Patient. 11(5). 527–537.
6.
Rudnick, Sean, Hélio Pedro, John J. Ko, et al.. (2018). The Patient Odyssey to Confirmed Acute Hepatic Porphyria Diagnosis: Clinical Characteristics and Healthcare Utilization of Patients Preceding Diagnosis of Acute Hepatic Porphyria. The American Journal of Gastroenterology. 113(Supplement). S500–S501.
7.
Sardh, Eliane, Manisha Balwani, Pauline Harper, et al.. (2018). A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria. Journal of Hepatology. 68. S66–S67.
8.
Fitzgerald, Kevin, Anna Borodovsky, Brian R. Bettencourt, et al.. (2016). A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine. 376(1). 41–51.
9.
Gottlieb, Jens, Martin R. Zamora, Tony N. Hodges, et al.. (2015). ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. The Journal of Heart and Lung Transplantation. 35(2). 213–221.
10.
Chan, Amy, Abigail Liebow, Makiko Yasuda, et al.. (2015). Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Molecular Therapy — Nucleic Acids. 4. e263–e263.
11.
Sehgal, Alfica, Keith Blomenkamp, Amy Simon, et al.. (2015). 279 Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency. Gastroenterology. 148(4). S–975.
12.
Fitzgerald, Kevin, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, et al.. (2013). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet. 383(9911). 60–68.
13.
Simon, Amy, et al.. (2010). Barotrauma During High Frequency Oscillatory Ventilation Resulting in Abdominal Compartment Syndrome. CHEST Journal. 138(4). 65A–65A.
14.
Myoishi, Masafumi, Amy Simon, & Michael E. Mendelsohn. (2009). Cyclic GMP-dependent protein kinase regulation of airway smooth muscle in asthma. BMC Pharmacology. 9(S1).
15.
Severgnini, Mariano, et al.. (2008). Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. American Journal of Physiology-Lung Cellular and Molecular Physiology. 295(4). L584–L592.
16.
Severgnini, Mariano, et al.. (2008). PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. American Journal of Physiology-Lung Cellular and Molecular Physiology. 294(4). L698–L704.
17.
Severgnini, Mariano, Satoe Takahashi, Powen Tu, et al.. (2005). Inhibition of the Src and Jak Kinases Protects against Lipopolysaccharide-induced Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine. 171(8). 858–867.
18.
Simon, Amy, Mariano Severgnini, Satoe Takahashi, et al.. (2005). 5-HT Induction of <I>c-fos </I>Gene Expression Requires Reactive Oxygen Species and Rac1 and Ras GTPases. Cell Biochemistry and Biophysics. 42(3). 263–276.
19.
Severgnini, Mariano, Satoe Takahashi, Robert Homer, et al.. (2004). Activation of the STAT pathway in acute lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology. 286(6). L1282–L1292.
20.
Kim, Yuri, Aiguo Ma, Kazumi Kitta, et al.. (2003). Anthracycline-Induced Suppression of GATA-4 Transcription Factor: Implication in the Regulation of Cardiac Myocyte Apoptosis. Molecular Pharmacology. 63(2). 368–377.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Masatoshi Kusuhara Breakdown of academic impact, for papers by Wolfgang Erl Breakdown of academic impact, for papers by Alistair J. Ingram Breakdown of academic impact, for papers by Jiawei Chen Breakdown of academic impact, for papers by Peter Ellinghaus Breakdown of academic impact, for papers by Orina Belton Breakdown of academic impact, for papers by Yabing Chen Breakdown of academic impact, for papers by Shiro Kitamoto Breakdown of academic impact, for papers by Aijun Sun Breakdown of academic impact, for papers by Naomi Sakashita